Champions Oncology Inc., a company engaged in the development of advanced
technology solutions and services to personalize the development and use of
oncology drugs, today announced the signing of a new discovery and drug
development partnership with Teva Pharmaceutical Industries LTD TEVA
which will utilize Champions TumorGraft™ technology platform to enhance and
accelerate the clinical development of several of Teva's oncology compounds.
This partnership, using the Champions TumorGraft™ technology platform, aims to
identify highly responsive cancer subtypes, and their corresponding molecular
and biochemical biomarkers of responsiveness to Teva's novel therapeutic
agents, hopefully leading to new and personalized therapeutic options for
patients with cancer. The development process will include initial screening
studies on large numbers of TumorGraft models to develop response hypotheses
for different tumor types and sub-populations. These hypotheses will be
further refined and validated with more in depth studies.
Under the terms of the agreement, Teva will pay Champions an upfront fee and
Champions may also receive milestone payments and royalties for the compounds
being studied if the response hypotheses are successfully utilized for
clinical trial design and resulting commercial success of the compounds.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in